A new tool, 'naked DNA', has recently become available to those involved in vaccine development. It shows great promise for both the improvement of existing vaccines and the development of vaccines against disease targets for which there are so far no effective vaccines. And yet the discovery that naked DNA could be used in vaccination came about more or less by accident, as a result of attempts to use non-replicating bacterial plasmid expression vectors (encoding proteins of interest) for gene therapy.
In experiments designed to test the use of cationic liposomes (lipidbased packages) for delivering plasmid DNA into cells, it was found that the 'control' animals, into which naked DNA alone was injected intramuscularly, expressed the highest levels of the transgenic protein. This unexpected discovery suggested a new approach to immune stimulation. If animals could be transfected by injection with DNA, such that the encoded protein was expressed in situ, would immunity specific to this protein (the antigen) result?
The answer is yes. In 1993, studies in mice showed that intramuscular injection of plasmid DNA encoding influenza virus antigens generated immune responses from both the humoral system (antibodies and B cells) and the cell-mediated system (cytotoxic T cells); these immune responses were sufficient to protect the animals against a live influenza virus infection (see Figure 1) . These results set off a flurry of research and development activity leading to the more than 700 papers on DNA vaccines in the literature today.
Advantages of DNA vaccines
There are numerous practical and scientific reasons for developing DNA vaccine technology, beginning with the fact that there are many potential disease targets for which there are no effective vaccines. Established vaccine technology has failed to produce effective vaccines against significant infections such as tuberculosis, chlamydia, papilloma virus and malaria. Furthermore, there are currently no effective anti-tumor vaccines. Vaccines directed against cancers may require technology that can stimulate a vigorous T-cell-mediated immune response against tumors expressing the antigen, but conventional vaccine technology using recombinant or purified subunit antigens (see blue box) often fails to stimulate cellmediated responses.
Given that some infectious pathogens and cancers are dealt with most effectively by T-cell-mediated immune responses, DNA vaccine technology was conceived as a means of stimulating antigen-specific cellmediated immunity. The scientific rationale was that the expressed antigen could be processed (digested into peptide fragments) in the cell and peptides from it displayed on cell-surface molecules of the major histocompatibility complex (MHC class I). This sort of 'antigen presentation' is necessary for the stimulation of T-cell-mediated immunity. Indeed, consistent with the original concept, DNA vaccination can be shown to stimulate antigen-specific cell-mediated immunity.
But other immunological evidence suggested that this immune response would not have been triggered simply by antigen-expressing muscle cells, because they do not carry all of the cell-surface molecules needed to stimulate cytotoxic T cells. Other, professional antigen-presenting cells must have been involved. Several labs subsequently provided evidence that the T-cell-mediated responses to DNA vaccines are mediated through bone-marrow-derived cells, but the details of how the antigen reaches these cells following DNA vaccination have not been definitively established. Even though the mechanistic details are not completely understood, one of the hallmarks of DNA vaccination is the reliable Magazine R551
Figure 1
Results of an experiment in which mice were vaccinated with either plasmid DNA encoding influenza virus antigen (red) or 'control' blank plasmid (blue). The mice were then challenged with influenza virus. All the control mice died and all those vaccinated with influenza antigen survived. Induced immunity to infectious agents can be achieved in several ways. One is to deliberately cause a mild infection using a live 'attenuated' form of the organism with reduced pathogenicity. This stimulates a long-lasting humoral and cell-mediated immunity but carries a risk: live attenuated bacterial and viral preparations can sometimes revert to active infectious forms. Vaccines of this type include the original smallpox virus vaccine pioneered by Jenner in 1796, Pasteur's chicken cholera bacteria vaccine, and current vaccines for measles, mumps and rubella.
A safer method is to use killed microbial or recombinant subunit preparations, which can not lead to infection. But these are not so potent, need the addition of adjuvants (substances that are mixed with an antigen to boost the immune response) and tend primarily to stimulate humoral immunity. Vaccines in this class include the original polio vaccine, influenza, tetanus toxoid, and hepatitis A and B vaccines. By contrast, naked DNA vaccines are not infectious and stimulate long-lasting humoral and cell-mediated immunity without the need for adjuvants.
Types of vaccine
development of a robust, antigenspecific cytotoxic T-cell response.
Another characteristic of DNA vaccination is its ability to induce an antigen-specific antibody (humoral) immune response. Humoral immunity, like cellular immunity, is mediated by helper T cells, which can be grouped into functional subsets, Th1 and Th2. Whereas vaccination with DNA leads to a Th1-dominated response, vaccination with recombinant proteins or killed viruses leads to a Th2-dominated response. Immune responses to allergy-causing proteins (allergens) are also Th2-dominated, and result in the production of IgE antibodies. DNA vaccination using plasmids encoding allergens can shift a pre-existing immune response to an allergen from the Th2 to the Th1 type, leading to an inhibition of IgE antibody production. This raises the possibility that DNA vaccination could be used to attenuate allergic responses to allergens.
DNA vaccination can also be used to generate antibody-producing cells for the production of hybridomas that produce monoclonal antibodies. Using DNA eliminates the need to isolate and purify the protein antigen for inoculation.
Because the specific type of MHC molecules expressed by a person (their HLA haplotype) determines which peptides (epitopes) within the antigen protein will be presented on the cell surface, conventional peptide-based vaccines must contain many different peptides to cover all of the haplotypes that are present in the normal outbred human population. But with DNA vaccines, one can use large, full-length protein antigens, allowing the immune system to select the appropriate epitopes according to the individual's own HLA haplotype. In addition, unlike the situation for many vaccines based on recombinant proteins, the antigen is produced in its native form. In situations where it would be advantageous to direct immune responses to specific epitopes of a protein, DNA vaccines could be developed which express many different peptide epitopes as 'minigenes'.
DNA vaccines are also more stable and easier to manipulate than purified proteins. Different proteins require different purification procedures but all plasmids, regardless of the sequences they encode, can be purified using the same procedures. Plasmid DNA is very stable, offering the potential for the development of a vaccine that can be stored at ambient temperatures. This may have practical implications for the delivery of stable vaccines to developing countries.
From test tube to cell
Experimentally, DNA vaccines are simple to manipulate. Plasmid is suspended in a simple saline solution and 10-500 µg is injected into the quadriceps muscle. This results in the uptake of the DNA by, and antigen expression in, muscle cells (Figure 2) . Another common method of administering DNA vaccines is by particle bombardment, in which cells of the dermis and epidermis are transfected as a result of direct penetration by DNA-coated gold beads. Using this method, antigen-presenting cells, such as Langerhans cells found in the skin, may be directly transfected, so inducing the cell-mediated and humoral immune responses.
Different antigens can be readily examined by simply cloning different genes into expression plasmids and injecting them into experimental animals. Multiple plasmids encoding different antigens can be administered at the same time. Antigen-specific immune responses begin within one or two weeks after injection. Although there is some antigen-dependent variation, the immune responses are stable, often lasting for the lifetime of the animal. Boosting with a second plasmid injection or with recombinant protein has been shown to augment the immune response. Intramuscular expression from plasmids peaks at about 14 days, and then sharply declines. Antigenspecific cytotoxic T cells mediate the decline in expression by killing the muscle cells expressing the foreign antigen, or by eliminating the muscle cell nuclei responsible for antigen expression. The immune system does not, however, completely eliminate the entire population of antigen-expressing cells and a low level of antigen expression continues for many months or even years after the onset of the immune response. The longevity of the immune response observed with DNA vaccination may be related to this persistent antigen expression, which would keep the immune response continuously primed.
Future developments
Many different microorganisms and cancer-associated antigens have been targeted with DNA vaccines (see green box). There are human clinical trials under way of DNA vaccines directed against influenza, HIV-1, malaria, hepatitis B, carcinoembryonic antigen and the MHC molecule HLA-B7 (as an immunostimulant, to direct immune responses against many different forms of cancer). More human clinical trials can be expected.
Scientifically, there are many basic questions that are not yet resolved. Although bone-marrowderived antigen-presenting cells seem to be involved in the response to DNA vaccines, it is not clear how the antigen gets into these cells after an intramuscular plasmid injection. There are also differences among animal species with regard to their susceptability to DNA immunization. Mice, dogs, chickens, cows and fish seem to be rather easy to immunize, whereas chimpanzees and cats are more difficult. The reasons for these differences are not understood and a better understanding should lead to more effective DNA vaccines. There is not necessarily a correlation between the level of gene product expressed at the site of injection and the strength of the resulting immune response.
Research is under way to determine whether the co-expression of immunostimulatory lymphokines, co-stimulatory molecules or adjuvants could help to boost the immune response to DNA. Another simple way of enhancing immune responses to DNA vaccines is via an adjuvant effect of the DNA itself. Evidence is emerging that certain CpG-rich sequences in the plasmid can have an adjuvant effect. Such motifs within the DNA seem to boost the efficacy of the DNA vaccine by inducing cytokine secretion and lymphocyte activation, but the details of these effects need to be evaluated further. So, with all of these interesting and practical features, will DNA vaccines eventually replace all other types of vaccine? The progress of pharmaceutical development usually moves steadily towards simpler, more chemically defined materials; it is therefore likely that chemically simpler products, such as DNA vaccines and peptide-or recombinant-protein-based vaccines, will replace killed and live-attenuated virus vaccines. And whereas recombinant-protein-based vaccines usually require 'boosting' at regular intervals to keep the immune response primed, the antibody response to a single dose of DNA vaccine remains primed for a long time, presumably because the antigen is persistently expressed. DNA vaccines are particularly effective at producing long-lived cell-mediated immunity, which is beneficial for vaccines against many viral, parasitic and bacterial pathogens, as well as for anti-cancer vaccines for which an antibody response alone is not sufficiently protective.
The discovery and development of DNA vaccines has had many surprising twists during the past ten years, and all the signs point to a very bright future over the next ten years.
